

Supplementary Figure:




Figure S1: Proportions of different pathogenic genetic alterations detected in MBCs using Illumina TruSeq amplicon cancer hotspot panel (total number of pathogenic alterations identified= 52, denominator).

**BRCA1* mutations are not included.

Supplementary Tables:

Patient #	ALTERATIONS SEEN IN MBC CASES AND THEIR CLINICAL SIGNIFICANCE	
1	<i>TP53</i> (I195T)	pathogenic/presumed pathogenic
2	<i>TP53</i> (C242fs); <i>AKT1</i> (E17K)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
3	<i>TP53</i> (S241C)	pathogenic/presumed pathogenic
4	<i>TP53</i> (E198X); <i>PIK3CA</i> (K1111del)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
5	<i>TP53</i> (R248Q)	pathogenic/presumed pathogenic
6	<i>TP53</i> (R282W); <i>STK11</i> (F354L)	pathogenic/presumed pathogenic; likely benign
7	<i>PIK3CA</i> (H1047R); <i>HRAS</i> (Q61L); <i>APC</i> (I1307K glm)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic; other
8	<i>TP53</i> (V216M)	pathogenic/presumed pathogenic
9	<i>FBXW7</i> (Q508X)	pathogenic/presumed pathogenic
10	<i>TP53</i> (S241C)	pathogenic/presumed pathogenic
11	<i>c-KIT*</i> (T67S); <i>TP53</i> (R248W); <i>SMAD4</i> (D415fs)	likely benign; pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
12	<i>TP53</i> (C242X)	pathogenic/presumed pathogenic
13	<i>HRAS</i> (Q61L)	pathogenic/presumed pathogenic
14	<i>TP53</i> (D281E)	pathogenic/presumed pathogenic
15	<i>TP53</i> (Y163C)	pathogenic/presumed pathogenic
16	<i>PIK3CA</i> (H1047L)	pathogenic/presumed pathogenic
17	<i>TP53</i> (S106R); <i>PIK3CA</i> (H1047R); <i>MLH1</i> (S406N)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic; likely benign
18	<i>PIK3CA</i> (H1047L)	pathogenic/presumed pathogenic
19	<i>TP53</i> (G244S)	pathogenic/presumed pathogenic
20	<i>cMET</i> (T1010I)	likely benign
21	<i>TP53</i> (V173M); <i>HRAS</i> (L52R)	pathogenic/presumed pathogenic; variant of unknown significance
22	<i>PTEN</i> (R233X); <i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
23	<i>HRAS</i> (G13V); <i>BRAF</i> (N581I)	pathogenic/presumed pathogenic; variant of unknown significance
24	<i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic
25	<i>TP53</i> (R273H)	pathogenic/presumed pathogenic
26	<i>TP53</i> (R33fs); <i>JAK3</i> (V722I)	pathogenic/presumed pathogenic; variant of unknown significance
27	<i>TP53</i> (R273C); <i>FBXW7</i> (T463S)	pathogenic/presumed pathogenic; variant of unknown significance
28	<i>TP53</i> (R213X)	pathogenic/presumed pathogenic
29	<i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic
30	<i>PIK3CA</i> (N345K)	pathogenic/presumed pathogenic
31	<i>TP53</i> (C242fs)	pathogenic/presumed pathogenic
32	<i>TP53</i> (I195T)	pathogenic/presumed pathogenic
33	<i>TP53</i> (R110fs)	pathogenic/presumed pathogenic
34	<i>TP53</i> (Q165X)	pathogenic/presumed pathogenic
35	<i>TP53</i> (C242fs); <i>JAK3</i> (V722I)	pathogenic/presumed pathogenic; variant of unknown significance

36	<i>TP53</i> (R273C)	pathogenic/presumed pathogenic
37	<i>TP53</i> (C242X)	pathogenic/presumed pathogenic
38	<i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic
39	<i>TP53</i> (Y220C); <i>cMET</i> (T1010I)	pathogenic/presumed pathogenic; likely benign
40	<i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic
41	<i>STK11</i> (F354L)	likely benign
42	<i>TP53</i> (R175H)	pathogenic/presumed pathogenic
43	<i>TP53</i> (C238Y); <i>PIK3CA</i> (H1047R)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
44	<i>TP53</i> (C176F)	pathogenic/presumed pathogenic
45	<i>STK11</i> (F354L)	likely benign
46	<i>PIK3CA</i> (P539R); <i>RET</i> (Y719F)	pathogenic/presumed pathogenic; likely benign
47	<i>TP53</i> (V274F); <i>PTEN</i> (K13E & R15fs)	pathogenic/presumed pathogenic; pathogenic/presumed pathogenic
48	<i>TP53</i> (R273H)	pathogenic/presumed pathogenic
	*other- mild mutation that is a common germline variant in the Ashkenazi Jewish population. Carriers have a slightly increased risk of colon cancer.	
	The row highlighted in yellow shows patients with non-pathogenic mutations and were not counted during the discussion	

Table S1: Specific alterations in genes and their clinical significance in all interpretable cases of MBCs.

PATHOGENIC ALTERATIONS IN MBCS	
Altered pathogenic gene	Frequency
<i>TP53</i>	32
<i>AKT1</i>	1
<i>Wild Type</i>	9
<i>PIK3CA</i>	13
<i>HRAS</i>	3
<i>FBXW7</i>	1
<i>SMAD4</i>	1
<i>PTEN</i>	1
Total number of mutations	52

Table S2: Pathogenic/presumed alterations and frequency seen in MBCs.

PATHOGENIC ALTERATIONS IN TNBCs	
Total number of patients with pathogenic mutations	94
Altered gene	Frequency
<i>TP53</i>	83
<i>PIK3CA</i>	13
<i>AKT1</i>	4
<i>STK11</i>	2
<i>BRCA1</i>	4
<i>BRCA2</i>	3
<i>HRAS</i>	1
<i>KRAS</i>	1
<i>APC</i>	2
<i>FGFR2</i>	2
<i>FGFR3</i>	1
<i>MAPK1</i>	1
<i>PTEN</i>	1
<i>ERBB2</i>	3
<i>ERBB3</i>	1
<i>CDKN2A</i>	1
<i>KDR</i>	1
<i>ABL1</i>	1
<i>DDR2</i>	1
<i>ARAF</i>	1
<i>FGF10</i>	1
<i>CCNE1</i>	1
<i>MCL1</i>	1
Total number of mutations	130

Table S3: Pathogenic alterations and their frequency in TNBCs.

PATHOGENIC ALTERATIONS IN HORMONE POSITIVE (HER2/NEU NEGATIVE) BREAST CANCERS	
Total number of patients with pathogenic mutations	58
Altered gene	Frequency
<i>BRCA2</i>	2
<i>BRCA1</i>	4
<i>ERBB2</i>	3
<i>CDH1</i>	1
<i>TP53</i>	25
<i>PIK3CA</i>	34
<i>SMAD4</i>	1
<i>AKT1</i>	4
<i>PTEN</i>	3
<i>MYC</i>	1
<i>ATM</i>	1
<i>APC</i>	1
Total number of mutations	80

Table S4: Pathogenic alterations and their frequency in Luminal breast cancer cases.

PATHOGENIC ALTERATIONS IN HER2 POSITIVE BREAST CANCERS	
Total number of patients with pathogenic mutations	20
Altered gene	Frequency
<i>TP53</i>	18
<i>PIK3CA</i>	11
<i>PTEN</i>	1
<i>ERBB2</i>	1
Total number of mutations	32

Table S5: Pathogenic alterations and their frequency in HER2+ breast cancer cases.

Subtype		Next Generation Sequencing		Total
		<i>TP53</i> mutation	other mutations	
	Metaplastic carcinoma	32 (71%)	16 (29%)	45
	TNBC NOS	83 (88%)	11 (12%)	94
	HER2+	18 (95%)	2 (5%)	20
	Hormone positive breast carcinoma	25 (43%)	33 (57%)	58
Total		159 (73%)	61 (28%)	217

Table S6: Cases with pathogenic *TP53* mutation versus pathogenic mutations in other genes.